Table 5.
Study type | Plant preparations | Dose | Study models | Effects | Ref. |
---|---|---|---|---|---|
Exp | A. cepa extract | 100 and 1,000 mg/kg/day | Antiallergic immune response | Improved Th1/Th2 balance; reduced proinflammatory cytokine levels | [131] |
A. cepa extract | 150 and 300 mg/kg b.w, | Intranasal | Decreased cellular infiltration and eosinophil and lymphocyte count in the blood and BALF | [91] | |
A. cepa extract | Onion 20 and 40 μl | Intranasal | Decreased mRNA levels of IL-4, IL-5, IL-10, IL-13, IFN-γ, and TNF-α | [119] | |
A. cepa extract | 10 mg/400 mL | Peritoneal cells | Decreased cytokine release, macrophage phagocytic activity, and NK cell activity | [152] | |
A. cepa extract | 20 μL | Lung eosinophilia infiltration | Reduced inflammatory cytokines and total cell counts in BALF and EPO in the lungs | [31] | |
A. cepa extract | 500 mg/kg | Lung and tissue | Decreased no, IL-6, TNF-α, IL-1β levels | [153] | |
A. cepa extract | 500 and 50 mg/kg/day | Pulmonary tissues | Low doses of onion was not toxic but high dose was toxic to rats | [154] | |
A. cepa extract | 250–600 mg | Allergic rhinitis | Reduced production of IL-4, IL-5, and IL-13 | [30] | |
Kaempferol | 75 mg/kg | OVA-sensitized mice | Reduced Th2, Th17, IL-4, IL-17, and TGF-β but increased Treg cells, Th1/Th2 ratio, FOXP3, IFN-γ/IL-4 ratio, and IFN-γ gene expressions | [155] | |
Kaempferol | 20 μmol/l | OVA-sensitized mice | Decreased IL-1β-induced NF-κb p65 DNA-binding activity and nuclear c-Jun expression | [156] | |
Kaempferol | — | OVA-sensitized rats | Reduced eosinophil count, IgE, IL-4, IL-5, IL-13, TNF-α, and IFN-γ levels | [157] | |
Kaempferol | 50 µM | OVA-sensitized rats | Inhibited LTB4 production without cytotoxicity | [158] | |
SAC | 10 or 20 mg/kg | OVA-sensitized mice | Reduced airway hyperresponsiveness, inflammatory cell counts, Th2-type cytokines in BALF, and serum OVA-specific IgE | [159] | |
SAC | — | C57BL/6 mice | Alleviated clinical symptoms; improved TNF-α, IL-17, ADNP, MAP1LC3A, and MMP-9 levels | [160] | |
SAC | — | MISD in mice | Inhibited TNF-α-induced activation of p38, JNK, and NF-κβ pathways | [161] | |
Kaempferol | 0.46 g | OVA-sensitized guinea pigs | Decreased histamine and leukotrienes; increased PGE2 | [162] | |
Amentoflavone | — | Mouse ear and rat paw edema | Inhibited phospholipase A2 and cyclooxygenase pathway | [163] | |
Quercetin | 30 mg/kg | Bone marrow-derived mast cells | Decrease allergen-induced airway hyper responsiveness, Th2 responses in the lung, lung eosinophilia, and goblet cell metaplasia | [164] | |
Kaempferol | 10 or 20 μM | Knee osteoarthritic rats | Decreased TNF-α, IL-1β, and MDA levels | [165] | |
Kaempferol | 25, 50, 100, and 200 μm | Rat articular chondrocytes cultures | Reduced interleukin-1β-stimulated proinflammatory mediators by inhibiting the NF-κβ pathway | [166] | |
FFR + onion | 150 and 400 mg/kg/d | Wistar rats | Decreased heart ENOS and VCAM-1 | [125] | |
Kaempferol | 2 mg/kg/day or 10 mg/kg/day | Rat gingival tissues | Reduced INOS and TNF-α expression and nuclear p6; increased cytosolic p65; downregulated Erk, p38, JNK, and NIK/IKK expression | [167] | |
Quercetin and kaempferol | 10 and 20 μM | Rbl-2h3 intestinal cells | Inhibited the secretion of TNF-α and IL-4 in antigen-stimulated RBL-2H3 cells | [41] | |
SAC | 10 to 600 µmol/L | Splenocytes of asthmatic mice | Inhibited TNF-α-induced inflammation in HaCaT cells | [141] | |
Thiosulfonates | 100 mg/kg | Guinea pig model of asthma | Inhibited inflammatory cell influx by thiosulfinates | [95] | |
Kaempferol | 1–20 μmol/l | Asthmatic mice | Inhibited eosinophil adhesion to TNF-α-activated airway epithelium | [140] | |
Kaempferol | 0.22 μm | BALB/c mice | Inhibited IL-4-induced transcription factor STAT6 activation by specifically targeting Janus kinase 3 | [139] | |
Polygonum tinctorium Lour. | 0.2, 2, or 20 mg/kg | OVA-induced mouse asthma | Reduced caspase-1 activity in nasal mucosa, IL-32, and IL-8 | [168] | |
Kaempferol | 20 μm | BALB/c mice model of asthma | Suppressed LPS-induced IL-8 through the TLR4 activation; inhibited eotaxin-1 induction | [169] | |
Kaempferol | — | LPS-stimulated THP-1 cells | Suppressed LPS-induced MDC, IP-10, IL-8, Th1, Th2, and neutrophil-related chemokines | [170] | |
Kaempferol | Mouse model of asthma | Deceased inflammatory cell invasion, goblet cell hyperplasia, mucus secretion, regulated TNF-α, IL-4, IL-5, and IL-13 | [171] | ||
Quercetin | 40 μM | Allergic asthma | Inhibited rat tracheal contractility | [59] | |
Quercetin | 8 or 16 mg/kg | Allergic asthma BALB/c | Decreased allergic airway inflammation and hyperresponsiveness; improved Th1/Th2 balance via the suppression of GATA-3 and increase of T-bet expression | [32] | |
Quercetin | 25 mg/kg | Allergic asthma BALB/c | Inhibited nasal rubbing movements and sneezing | [172] | |
Quercetin | 20 mg/kg | Allergic asthma BALB/c | Inhibited nasal symptoms; increased TRX levels in nasal lavage fluids | [173] | |
Clin | A. cepa extract | Onion juice 52 g | Neuronal cell oxidative stress | Improved clinical symptoms; increased phagocytic and intracellular killing activities of PMNs and CD8 counts | [81] |
A. cepa extract | — | Allergic rhinitis | Reduced IgE and eosinophil count in nasal discharge; stabilized mast cell membranes | [127] | |
A. cepa extract | — | Allergic disorders | Relieving perennial allergic rhinitis symptoms; increased phagocytic and intracellular killing activities of PMNs and CD8 counts | [174] | |
A. cepa extract | 50 g | Allergic induction | Severe allergic reactions induced by cooked onion | [175] | |
A. cepa extract | — | Allergic hypersensitivity | Improved clinical symptoms | [128] |
Ref.: references, Exp: experimental, Clin: clinical, IFN-γ: interferon- γ, TNF-α: tumor necrosis factor-α, BALF: bronchoalveolar lavage fluid, EPO: eosinophil peroxidase, BAL: bronchoalveolar lavage, MDA: malondialdehyde, NO2: nitrite, NO3: nitrate, SOD: superoxide dismutase, CAT: catalase, TC: total cholesterol, LDL-C: low-density lipoproteins, TG: triglycerides, HDL-C: high-density lipoproteins, PPAR γ: peroxisome proliferator-activated receptor γ, TSM: tracheal smooth muscle, i.p.: intraperitoneally, MMP-9: matrix metalloproteinase 9, MAP1LC3A: microtubule-associated proteins 1 A/1 B light chain 3A, ADNP: activity-dependent neuroprotector homeobox, ENOS: endothelial nitric oxide synthase, VCAM-1: vascular cell adhesion molecule-1, IL-17: interleukin 17, PGE2: prostaglandin E2, LTB4: leukotriene B4, THP-1: human monocytic cell line, OVA: ovalbumin, C57BL: C57 black 6, LPS: lipopolysaccharide, SAC: S-allyl cysteine, and MISD: multiple inflammatory skin diseases.